{"commentary":{"count":82,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":40,"youtube":23,"podcast":19},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03799835\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ALBAN","nct_id":"NCT03799835","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alban-nct03799835. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ALBAN","arms":[{"description":"BCG therapy only\n\nBCG therapy will be administered in two phases:\n\n* induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)\n* maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).","label":"Arm A : control arm","type":"ACTIVE_COMPARATOR"},{"description":"BCG therapy + administration of atezolizumab\n\n1. BCG therapy will be administered in two phases:\n\n   * induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)\n   * maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).\n2. atezolizumab is administered by IV infusion every 3 weeks (21 \\[± 2\\] days) for 1 year (18 cycles as a maximum).","label":"Arm B: experimental arm","type":"EXPERIMENTAL"}],"collaborators":["Hoffmann-La Roche"],"completion_date":{"date":"2028-10","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":517,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"BCG","type":"DRUG"},{"name":"Atezolizumab","type":"DRUG"}],"last_update":"2024-12-11","lead_sponsor":"UNICANCER","official_title":"An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-Free Survival","timeFrame":"5 years"}],"references":[],"start_date":{"date":"2019-01-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03799835"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alban-nct03799835"}